Hodgkin's disease at autopsy: 1972–1977

Colby, Thomas V.; Warnke, Roger A.; Hoppe, Richard T.

doi:10.1002/1097-0142(19810401)47:7<1852::aid-cncr2820470723>3.0.co;2-d

Cited by 50 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio of patients who died with HD and infection is similar to that described in a large series from Stanford University, in patients with HD without HIV (45%), but the infecting organisms were different. 43 Overall survival was 18 months, according to other which was poor compared with the general series where disease-free survival after 10 years is approximately 65%. 40 In the statistical analysis for predictors of survival, three factors had prognostic importance: AIDS, pancytopenia pretreatment, and CR.…”

Section: Monthsmentioning

confidence: 89%

Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients

Serrano¹,

Bellas²,

Campo³

et al. 1990

Cancer

View full text Add to dashboard Cite

The experience of 22 Hodgkin's disease (HD) patients with human immunodeficiency virus type I (HIV) antibodies, collected from a cooperative study of six hospitals during 1984-1989 is presented. Young men (average age, 27.6 years) with a high incidence of intravenous drug abuse (86%) were found. The status of the HIV infection at diagnosis of HD was: four patients, acquired immune deficiency syndrome (AIDS); eight patients, persistent generalized lymphadenopathy (PGL); and ten patients, asymptomatic. The natural history of HD was unusual, with a high incidence of B symptoms (81%), advanced Stages III to IV (90%), bone marrow invasion (50%), cytopenias before treatment (45%), opportunistic infections (68%), and aggressive histologies. A decreased response to chemotherapy with poor marrow tolerance and a significant decrease in survival, 18 months, was observed. The AIDS and cytopenias pretreatment were associated with a shorter statistically significant survival, which defines the importance of immunodeficiency in HD prognosis. Complete remission after treatment was a factor that contributed to a longer statistically significant survival. The PGL or asymptomatic patients survived longer but also had a poor course, and five of them had AIDS criteria during evolution. A high incidence of HD in relation to non-Hodgkin's lymphoma (NHL) in patients with HIV infection in the six cooperating hospitals was found. Criteria for considering HD as an AIDS-associated lymphoproliferative disease in our environment are discussed.

show abstract

Section: Monthsmentioning

confidence: 89%

Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients

Serrano¹,

Bellas²,

Campo³

et al. 1990

Cancer

View full text Add to dashboard Cite

show abstract

“…Clinically, this immune deficiency is reflected in an increased susceptibility to fungal, viral and bacterial infections. Prior to the advent of modern chemo‐radiotherapeutic strategies, infection was a major cause of death due to HL (Colby et al , 1981). Diminished cellular immunity, as evidenced by a reduced capacity to reject skin allografts and impaired delayed type hypersensitivity reactions, has long been known (Eltringham & Kaplan, 1973).…”

Section: Immune Evasionmentioning

confidence: 99%

Epstein–Barr virus‐associated Hodgkin's lymphoma

2004

View full text Add to dashboard Cite

Survivors of Hodgkin's lymphoma (HL) frequently have many years to experience the long-term toxicities of combined modality therapies. Also, a significant proportion of HL patients will relapse or have refractory disease, and less than half of these patients will respond to current salvage strategies. 30-50% of HL cases are Epstein-Barr virus associated (EBV-positive HL). The virus is localized to the malignant cells and is clonal. EBV-positive HL is more frequent in childhood, in older adults (>45 years) and in mixed cellularity cases. The survival of EBV-positive HL in the elderly and the immunosuppressed is particularly poor. Despite improvements in our understanding of EBV-positive HL, the true contribution of EBV to the pathogenesis of HL remains unknown. Increased knowledge of the virus' role in the basic biology of HL may generate novel therapeutic strategies for EBV-positive HL and the presence of EBV-latent antigens in the malignant HL cells may represent a target for cellular immunotherapy.

show abstract

“…2 Two components of the inflammatory background are associated with survival in classical Hodgkin's lymphoma: tumorinfiltrating lymphocytes 3,4 and a low lymphocyte count, which is defined by the IPS as less than 600 cells/mL or less than 8% of the white blood cell count and is a negative prognostic factor for survival in classical Hodgkin's lymphoma.…”

Section: Introductionmentioning

confidence: 99%

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

Porrata¹,

Ristow²,

Colgan³

et al. 2011

Haematologica

184

154

View full text Add to dashboard Cite

BackgroundLymphopenia and tumor-associated macrophages are negative prognostic factors for survival in classical Hodgkin's lymphoma. We, therefore, studied whether the peripheral blood absolute lymphocyte count/absolute monocyte count ratio at diagnosis affects survival in classical Hodgkin's lymphoma. Design and MethodsWe studied 476 consecutive patients with classical Hodgkin's lymphoma followed at the Mayo Clinic from 1974 to 2010. Receiver operating characteristic curves and area under the curve were used to determine cut-off values for the absolute lymphocyte count/absolute monocyte count ratio at diagnosis, while proportional hazards models were used to compare survival based on the absolute lymphocyte count/absolute monocyte count ratio at diagnosis. ResultsThe median follow-up period was 5.6 years (range, 0.1-33.7 years). An absolute lymphocyte count/absolute monocyte count ratio at diagnosis of 1.1 or more was the best cut-off value for survival with an area under the curve of 0.91 (95% confidence interval, 0.86 to 0.96), a sensitivity of 90% (95% confidence interval, 85% to 96%) and specificity of 79% (95% confidence interval, 73% to 88%). Absolute lymphocyte count/absolute monocyte count ratio at diagnosis was an independent prognostic factor for overall survival (hazard ratio, 0.18; 95% confidence interval, 0.08 to 0.38, P<0.0001); lymphoma-specific survival (hazard ratio, 0.10; 95% confidence interval, 0.04 to 0.25, P<0.0001); progression-free survival (hazard ratio, 0.35; 95% confidence interval, 0.18 to 0.66, P<0.002) and time to progression (hazard ratio, 0.27; 95% confidence interval, 0.17 to 0.57, P<0.0006). ConclusionsThe ratio of absolute lymphocyte count/absolute monocyte count at diagnosis is an independent prognostic factor for survival and provides a single biomarker to predict clinical outcomes in patients with classical Hodgkin's lymphoma.Key words: prognosis, classical Hodgkin's lymphoma, biomarker, absolute lymphocyte count, absolute monocyte count, ratio.Citation: Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, and Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012;97(2):262-269. doi:10.3324/haematol.2011 This is an open-access paper.Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

show abstract

Hodgkin's disease at autopsy: 1972–1977

Cited by 50 publications

References 12 publications

Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients

Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients

Epstein–Barr virus‐associated Hodgkin's lymphoma

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

Contact Info

Product

Resources

About